Dr Reddy's Plan for Major Expansion in US Market

Hyderabad based Dr Reddy's Laboratories expects to launch over 15 products in the US market in 2018-19, according to the CFO of the company. According to Dr Reddy's plan of action the company official also remains optimistic for a double-digit growth in the domestic market in the ongoing financial year.

"Normally every year, based on our portfolio and R&D investments, we prepare for 10 to 15 launches. But this year (2018-19), it could be 15 plus," the company's CFO Saumen Chakraborty told analysts and journalists.

The company, which launched three products in the US during March quarter of 2017-18, has over 100 abbreviated new drug applications (ANDAs) lined up for approval with the US Food and Drug Administration (USFDA).

"We have over 100 ANDAs pending, many of them first-to-file, many of them complex assets, both at the API level as well as the finished dosage level," CEO GV Prasad said.